Testing hCG for acute GVHD after a stem cell transplant
Treatments studied
Part of Immune system & allergy clinical trials.
This study tests if a hormone called hCG can help treat moderate-to-severe graft-versus-host disease (GVHD) after a stem cell transplant. It is for adults who have recently developed GVHD and need steroids, but have not been on high-dose steroids for long.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have had a stem cell transplant (from a sibling or a matched unrelated donor).
- You have a new, moderate-to-severe case of graft-versus-host disease (GVHD) that needs treatment with steroids.
- You have not been on high-dose steroids for more than 3 days in the last week.
- If you or your partner could become pregnant, you are willing to use birth control or stay abstinent during the study and for 30 days after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether an experimental cell therapy called iMSC can help prevent graft-versus-host disease (a common complication after a stem cell transplant). It is given soon after your transplant, within 5 days of enrolling, and aims to reduce the chance of this serious condition.
This Phase 3 trial tests whether a specific low-dose medication (methotrexate) together with standard steroid treatment can improve early outcomes in patients with acute graft-versus-host disease after a stem cell transplant. It may help control the immune reaction that attacks the body after transplant.
This study looks at whether doing moderate-to-vigorous exercise can reduce complications from corticosteroids in people with newly diagnosed GVHD. It may help your body tolerate steroids better, while checking exercise safety during treatment.
This trial tests whether moxibustion—a traditional Chinese medicine technique using heat from burning mugwort—can help treat acute graft-versus-host disease (a complication after bone marrow transplant) that hasn't responded to steroid drugs. If you've had a stem cell transplant and developed this condition that won't go away with standard treatment, this study may be for you.
This trial tests a new treatment using special white blood cells (called Treg cells) to help control graft-versus-host disease (GVHD), a common complication after a stem cell transplant. The goal is to reduce GVHD symptoms without the serious side effects of high-dose steroids.
This study tests a new cell therapy (CK0802) for people with severe graft-versus-host disease (GVHD) that hasn't improved with standard steroid treatment. The treatment aims to control the immune response causing GVHD, potentially reducing symptoms and improving outcomes.
Hear when a new Acute Graft Versus Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.